Healthpeak Properties Inc

DOC is extreme oversold near its key support zone, granting a medium-term bullish bias under mean-reversion eligibility, but short-term momentum remains unfavorable with price below declining EMAs, so execution is deferred pending stabilization and acceptance around the $20.37 support level.

• ↑Q2 2026 revenue increased 35% YoY to $771.58 M with net income at $52.82 M
• ↑Adjusted FFO guidance raised to $1.73–$1.77 per share for 2026
• ↓Earnings yield is negative and profitability factors remain weak